Bremelanotide Acetate Patent Expiration
Bremelanotide Acetate is used for treating hypoactive sexual desire disorder (HSDD) in premenopausal females with controlled hypertension by injecting bremelanotide. It was first introduced by Cosette Pharmaceuticals Inc
Bremelanotide Acetate Patents
Given below is the list of patents protecting Bremelanotide Acetate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Vyleesi (autoinjector) | US10286034 | Uses of bremelanotide in therapy for female sexual dysfunction | Nov 05, 2033 | Cosette |
Vyleesi (autoinjector) | US11590209 | Use of bremelanotide in patients with controlled hypertension | Apr 29, 2041 | Cosette |
Vyleesi (autoinjector) | US6579968 | Compositions and methods for treatment of sexual dysfunction |
Jun 28, 2021
(Expired) | Cosette |
Vyleesi (autoinjector) | US6794489 | Compositions and methods for treatment of sexual dysfunction | Jun 28, 2025 | Cosette |
Vyleesi (autoinjector) | US9352013 | Uses of bremelanotide in therapy for female sexual dysfunction | Nov 05, 2033 | Cosette |
Vyleesi (autoinjector) | US9700592 | Uses of bremelanotide in therapy for female sexual dysfunction | Nov 05, 2033 | Cosette |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bremelanotide Acetate's patents.
Latest Legal Activities on Bremelanotide Acetate's Patents
Given below is the list recent legal activities going on the following patents of Bremelanotide Acetate.
Event | Date | Patent/Publication |
---|---|---|
![]() | ||
Payment of Maintenance Fee, 8th Yr, Small Entity | 19 Nov, 2023 | US9352013 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 17 Nov, 2023 | US9352013 |
Patent Issue Date Used in PTA Calculation | 28 Feb, 2023 | US11590209 |
Recordation of Patent Grant Mailed | 28 Feb, 2023 | US11590209 |
Email Notification | 28 Feb, 2023 | US11590209 |
Issue Notification Mailed | 08 Feb, 2023 | US11590209 |
Dispatch to FDC | 26 Jan, 2023 | US11590209 |
Application Is Considered Ready for Issue | 26 Jan, 2023 | US11590209 |
Issue Fee Payment Verified | 24 Jan, 2023 | US11590209 |
Issue Fee Payment Received | 24 Jan, 2023 | US11590209 |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳